[Pharmacologic constraints imposed by the blood-brain barrier: the example of multiple sclerosis].
Jolliet
P
P
Laboratoire de Pharmacologie Faculté de Médecine 1, rue Gaston Veil, 44035 Nantes cedex 1. pascale.jolliet@sante.univ-nantes.fr
D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D000998:Antiviral Agents / Q000493:pharmacokinetics; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001692:Biological Transport / Q000187:drug effects; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000502:physiology; D002352:Carrier Proteins / Q000378:metabolism; D004058:Diffusion; D005938:Glucocorticoids / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D010539:Permeability / Q000187:drug effects; D013256:Steroids
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D002352:Carrier Proteins; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D013256:Steroids